Keros Therapeutics Inc KROS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $61.25
- Day Range
- $59.60–61.17
- 52-Week Range
- $27.03–72.39
- Bid/Ask
- $59.28 / $59.94
- Market Cap
- $2.24 Bil
- Volume/Avg
- 17,988 / 352,877
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7,443.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 149
- Website
- https://www.kerostx.com
Comparables
Valuation
|
Metric
|
KROS
|
CTNM
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 15.00 |
Price/Book Value | 5.27 | 2.11 | 2.75 |
Price/Sales | 7,443.24 | — | 6.63 |
Price/Cash Flow | — | — | 14.21 |
Price/Earnings
KROS
CTNM
UTHR
Financial Strength
|
Metric
|
KROS
|
CTNM
|
UTHR
|
|---|---|---|---|
Quick Ratio | 19.17 | 58.48 | 3.92 |
Current Ratio | 20.37 | 58.92 | 4.35 |
Interest Coverage | — | — | 22.67 |
Quick Ratio
KROS
CTNM
UTHR
Profitability
|
Metric
|
KROS
|
CTNM
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −33.90% | −18.15% | 16.95% |
Return on Equity (Normalized) | −36.95% | −871.68% | 20.53% |
Return on Invested Capital (Normalized) | −35.57% | −892.99% | 16.62% |
Return on Assets
KROS
CTNM
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Twxydswqj | Hxsl | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ncqkqmkb | Knhtldw | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mdcgrfsy | Vjbjxs | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Brbvsdq | Cvlgtgw | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Ttkngnmn | Ckw | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Njmzzfvw | Wjsp | $28.3 Bil | |||
| Moderna Inc
MRNA
| Zqxflmb | Sxs | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Kfjsscxz | Bjdvp | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lvzvsfys | Ljqzfz | $13.3 Bil | |||
| Incyte Corp
INCY
| Ytbfbdjrx | Zpcwwny | $13.0 Bil |
United States